Remodeling the bone marrow tumor microenvironment with CART cell therapy to overcome resistance in multiple myeloma
Jennifer M. Feigin(Mayo Clinic in Arizona), Saad S. Kenderian(Mayo Clinic in Arizona), P. Leif Bergsagel(Mayo Clinic in Arizona), Mehrdad Hefazi Torghabeh(Mayo Clinic), Carli M. Stewart(WinnMed), Wannakorn Khopanlert, Olivia Sirpilla, Truc T. Huynh(Genomics Institute of the Novartis Research Foundation), Grace DeFranco, İsmail Özgür Can(Mayo Clinic), Omar Gutierrez Ruiz(Mayo Clinic in Arizona), Brooke Kimball(Mayo Clinic), Claudia Manriquez Roman(Mayo Clinic), Yi Lin, Reona Sakemura(Mayo Clinic), Hong Xia(Jingchu University of Technology), Kun Yun(Xijing Hospital), Sophia Goldberg, Diane F. Jelinek(Mayo Clinic in Arizona), Long Mai(Mayo Clinic), Matthew J. Schellenberg(Mayo Clinic), Dominic Skeele, Elizabeth L. Siegler(Mayo Clinic)
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k